← Browse by Condition
Medical Condition
refractory mantle cell lymphoma
Total Trials
3
Recruiting Now
3
Trial Phases
Phase 2
NCT05910801 Phase 2
Recruiting
Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Enrollment
100 pts
Location
United States
Sponsor
Academic and Community Cancer ...
NCT07003295 Phase 2
Recruiting
Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
Enrollment
20 pts
Location
United States
Sponsor
National Cancer Institute (NCI...
NCT04484012 Phase 2
Recruiting
Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Enrollment
36 pts
Location
United States
Sponsor
City of Hope Medical Center